The presence of eosinophilic infiltrations in the squamous epithelium of the esophagus is an uncommon finding and may be associated with a variety of conditions in children, such as eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD) and proton pump inhibitor responsive esophageal eosinophilia (PPI-REE). 1 EoE is an emerging clinical entity, the prevalence of which has increased during the last 15 years, and one which requires intensive monitoring and treatment to prevent long-term complications. 2 It has a complex pathogenesis, and both environmental factors and predisposed genetic backgrounds can lead to the disease. 3 Diagnosis is based on the presence of eosinophil dominant inflammation [≥ 15 eosinophils per high power field (HPF) in ≥1 esophageal biopsy] in addition to clinical symptoms related to esophageal dysfunction after exclusion of other causes of esophageal eosinophilia (EE). 4 The true prevalence of the disease varies from region to region, the highest prevalence being reported in the United States and Austria, and a lower figure in the United Kingdom. 5 The purpose of this study was to analyze the clinical findings, etiologies and outcomes of children with EE in our pediatric gastroenterology and allergy unit during a 6-year period. Additionally, we focused on patients with EoE in terms of clinical and laboratory findings, treatment modalities and outcomes.
Material and Methods
This retrospective study was based on the findings in patients' hospital file records. Children undergoing esophagogastroduodenoscopy (EGD) during a 6-year period (from January 2010 to December 2015) in our pediatric gastroenterology unit were included (n=3466). The files of patients with EE were re-evaluated in detail to elicit demographic features, clinical (major symptom at initial admission), laboratory and histopathological findings, treatment modalities and outcomes. EE was defined as the presence of eosinophils in the epithelium of the esophagus. 4 Diagnosis of EoE, PPI-REE and other diseases was based on ACG Clinical Guidelines. 4 Although we had planned to take at least three biopsies from the esophagus, stomach and duodenum during each endoscopy even if macroscopic appearances were normal, in practice this was not performed in the majority of cases (i.e., biopsy was taken only from the duodenum in cases with chronic diarrhea or only from the stomach in cases with dyspepsia). Esophageal biopsies were therefore obtained from only approximately 20% of the patients who underwent EGD (n=708). Esophageal biopsy specimens from patients with EE were re-evaluated by a pathologist (SM). Peak intraepithelial eosinophil count (IEC) per HPF (400x, size of 1 HPF -0.45 x 0.45 mm) and average IEC per HPF (at least 3 HPF) were analyzed in addition to other histopathological findings of EE and EoE. Fo l l o w i n g c o n f i r m a t i o n o f E E a f t e r histopathological examination, all patients underwent atopy evaluation (history of physician-diagnosed atopic diseases, family history of atopic diseases and skin prick and/ or food-specific IgE blood test) by a pediatric allergist. Skin prick tests included common aeroallergens (Dermatophagoides pteronyssinus, Dermatophagoides farina, grass mix, Alternaria, Cladosporium and weeds) and food allergens (cow's milk, chicken egg, peanut, hazelnut, soy, wheat, rice, corn, chicken meat and beef). Additional food allergens were added to the skin prick test depending on the patient's clinical history and food intake. Histamine (1 mg/ml) and saline were used for positive and negative controls. Tests were read after 15 minutes, and the prick test was considered positive if the widest diameter of the wheal was ≥3 mm. The concentration of food specific IgEs was considered positive at a value >0.35 kU/L. Patients were considered to have allergen sensitization in the event of a positive skin prick test and/or specific IgE. Complete blood count analysis was used for the calculation of peripheral eosinophil count (PEC) (eosinophil% x total white blood cell count), and was considered elevated at a value >300 cells/ mm 3 . Total IgE was considered elevated when the levels were at upper limits for age and gender-specific values.
The treatment regimen employed was selected by the consulting physician. Generally, in patients with EE this depends on the underlying pathology (i.e., gluten free diet for celiac disease, and triple therapy for Helicobacter pylori gastritis). Patients with EoE underwent surgical dilatation if they had esophageal stricture. The six food elimination diet (SFED) or targeted elimination diet (TED) were used based on the atopic sensitization results. Topical (budesonide, 1-2 mg/day or fluticasone, 4 times 220-440 μg/day) or systemic corticosteroids (CS) (initial standard dose: 1 mg/kg for 2 weeks then tapered weekly and continued for 4-6 weeks; low dose: 0.5 mg/kg for 2 weeks, tapered to 0.25 mg/kg and continued for 6-8 weeks) were added to the treatment depending on the severity of the symptoms. At follow-up, CS was discontinued on the basis of amelioration of symptoms and/or histological improvement, and treatment continued with diet elimination only. Diet elimination was subsequently discontinued within 6 months based on the symptoms exhibited.
For clinical and other characteristics, continuous variables were expressed as mean and standard deviation, or median and range when appropriate. The chi-square test was used to compare the incidence of EE during three time periods (2010-2011, 2012-2013 and 2014-2015) . A p value of <0.05 was considered significant. Approval for the study was obtained from the Ethics Committee of Karadeniz Technical University Faculty of Medicine (decision # 2015/156).
Results
EGD was performed on 3,466 children during the 6-year study period, and esophageal biopsy during EGD was obtained from 708 children (20.4%). EE was determined in 33 patients [0.95% (95% CI: 0.63-1.27) among all the children enrolled, and in 4.66% (95% CI: 3.11-6.21) of children undergoing esophageal biopsy (mean age ± SD of the patients with EE; 8.6 ± 4.2 years and 72.7% male).
The patients' main characteristics are shown in Table I . Chronic abdominal pain and acute dysphagia/food impaction were the most common presenting symptoms. Allergen sensitization was determined in 54.5% of patients, and 42.4% of subjects had associated atopic diseases.
Two patients (6%) with EE had severe and diffuse antral nodularity and exhibited positive Helicobacter pylori (H. pylori) staining at histological examination. Both were prescribed triple therapy (including proton pump inhibitor + 2 antibiotics), and EE and H. pylori gastritis improved at histological examination after treatment. Six patients (18%) had increased eosinophils in the duodenal and gastric biopsies in addition to EE. These subjects also had other clinical and laboratory findings of eosinophilic gastroenteropathy. One patient (3%), admitted with chronic diarrhea, had elevated tissue transglutaminase IgA. Histopathological examination revealed EE in addition to total villous atrophy. The patient was prescribed a gluten-free diet. One patient with EE (3%) was admitted with chronic vomiting and recurrent oral aphthous lesions. Detailed personal history revealed recurrent fever attacks and a diagnosis of familial Mediterranean fever (FMF) based on clinical and positive MEFV mutation analysis. This patient was prescribed colchicine. One patient (3%) with acute leukemia was admitted with acute solid food dysphagia while receiving maintenance treatment. Endoscopy revealed a 1/3 distal esophageal stricture. Esophageal biopsy revealed esophagitis and increased eosinophils (8 eos/HPF). Esophageal dilatation was performed, and PPI treatment was initiated. Four of the other 22 patients were prescribed PPI before endoscopy, and were diagnosed with EoE based on clinical and histological findings. Eighteen patients were prescribed PPI (1-2 mg/ kg) for 6 to 8 weeks. Thereafter, 13 underwent a second endoscopy, while five declined a second endoscopy or were lost to follow-up. Four patients responded to the PPI trial (<5 eos/ HPF), and PPI-REE was diagnosed. Seven out of 13 patients did not respond to the PPI trial (≥15 eos/HPF) and were diagnosed with EoE. Additionally, two patients who did not respond to the PPI trial (≥15 eos/HPF) were diagnosed with PPI-nonresponsive GERD-related EE. One of these patients had severe motor and mental retardation, and barium esophagography revealed severe reflux and distal esophageal dilatation (lower esophageal sphincter failure). 
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A trial of hydrolyzed formula was planned, but the patient died due to aspiration pneumonia. The other patient underwent anti-reflux surgery performed by a pediatric surgeon due to refractory reflux symptoms, and this subject had a high reflux index at 24-hour pH monitoring. EE and esophageal symptoms improved after reflux surgery. Both patients were negative for the skin prick test and specific IgE testing.
Final diagnoses are shown in Figure 1a and 1b.
Demographic features, and clinical and laboratory findings of the patients with EoE (n=11) are shown in and one patient (9%) received a combination of low-dose CS and diet (SFED). Three patients (27.2%) are still being treated under the initial regimen.
The incidence of EE for the three time periods in the previous 6 years is shown in Table III . The overall incidence of EE increased in 2014-2015 compared to 2010-2011 (0.41% vs. 1.33, p=0.047 and OR: 3.12). At subgroup analysis, the overall incidence of EoE increased gradually over the three time periods, but this did not reach statistical significance (0.13%, 0.28% and 0.44%, respectively and p>0.05) (Fig. 3) . findings and outcomes of EoE in children and (iii) changing incidences of EE during a 6-year period.
Discussion

T h i s s t u d y d e s c r i b e s ( i ) t h e c l i n i c a l characteristics and diseases associated with EE, (ii) clinical, laboratory and histological
Apart from EoE, GERD and PPI-REE, excessive accumulation of eosinophils in esophageal tissue has been shown in numerous disorders, such as celiac disease (CD), eosinophilic gastrointestinal disease, inflammatory bowel disease, achalasia, drugs, vasculitis and infections, as in our cases. 1, 4 An association between EE and CD has previously been described in adult and pediatric reports. 1,6,7 Quaglietta L et al. 6 reported CD in six out of 17 pediatric patients (35.2%) with EoE, and stated that histological and clinical improvement were seen after a gluten-free diet. In contrast, an increased prevalence of EoE in patients with CD has also been reported in pediatric patients. 7 These two disorders are caused by aberrant immune response, and diet elimination improved the symptoms in both. The association might be related to the effect of gluten on esophageal mucosal integrity. 8 Despite these reports, the association between these two disorders has not been confirmed in large population-based epidemiological studies. 9 H. pylori gastritis has been determined in 6% of children with EE, a lower figure than in population-based H. pylori prevalence studies. 10 An inverse association has been reported between H. pylori infection and EE in previous pediatric studies. 11, 12 H. pylori infection reduces the development of atopy by approximately 20%, which is protective against IgE mediated reactions. 13 No association between EE with FMF has previously been reported. However, Gurkan OE et al. 14 reported a case of esophagitis and widespread aphthous ulcerations in gastric mucosa in an infant with FMF. Improvement of clinical symptoms after treatment proved that this is related to FMF. Esophageal stricture and EE may rarely be seen secondary to anti-neoplastic agents, such as doxorubicin, methotrexate, and cytosine arabinoside, either alone or in combination with radiotherapy. Mild mucosal eosinophilia may be seen in addition to eosophagitis. 15 Unresponsiveness to PPI therapy is the mainstay for differentiating EoE from GERD and PPI-REE according to recent guidelines. 16 A small number of patients with GERD may present with EE due to (i) epithelial tight junction damage secondary to gastric acid exposure, which may allow the allergen penetration that may subsequently trigger eosinophilic infiltration, while (ii) GERD and EE may coexist in a patient without being related to one another, and (iii) EE may cause GERD due to esophageal dysfunction. PPIs have beneficial effects on EE in these patients through (i) antiinflammatory and (ii) antioxidant effects and (iii) by blocking the IL-4 and IL-13 stimulated secretion of eotaxin-3. 17 Approximately onethird of patients with EE respond to PPI therapy. Despite the guidelines and studies, the PPI trial in the management of EE is still to some extent controversial. Two of our patients did not respond to the PPI trial, and both were negative for the skin prick test and specific IgE testing. One had severe mental motor retardation and severe reflux and distal esophageal dilatation at barium esophagography, and the other had a high reflux index at 24-hour pH monitoring. One underwent anti-reflux surgery, and both the symptoms and histology improved thereafter. These two patients are unlikely to have had EoE because they were negative for allergy testing and had radiological and laboratory findings compatible with severe GERD. We think that the PPI trial may fail to differentiate EoE and GERD in some patients, especially when GERD is severe.
The main clinical characteristics of EoE are adolescent age, male sex, presence of atopy, dysphagia/food impaction, trachealization, white papules and furrowing. The presenting symptoms and other findings in our patients are in agreement with previous studies. 18, 19 As reported previously, endoscopic appearance may be normal and clinical findings may be non-specific in some cases, and patients may be diagnosed incidentally at histological examination. 16, 18, 19 Mucosal biopsy during endoscopy from at least two levels is currently recommended, even though the macroscopic appearance of the mucosa is normal. Approximately 80% of our patients had ≥1 specific allergen confirmed by skin prick tests and specific IgEs. We were unable to perform the skin patch test in our patient group, but the rate of atopy was similar to those in previous studies. 20, 21 Aeroallergens were determined in approximately 35% of our patients. Levels of 10% to 20% have been reported in previous studies. 21 Aeroallergens have been shown to be associated with seasonal variation in clinical admissions in previous studies. 21 As with other allergic diseases, the incidence of EE seems to have increased during recent decades. 4, 5 It is difficult to estimate the true incidence of EE, because esophageal biopsy is the gold standard for diagnosis. The availability of endoscopic evaluation for gastrointestinal problems in children is increasing in all centers in Turkey, and with the increased rate of esophageal biopsy, this will reveal the true incidence of the disease in the next few years. In our study, the overall incidence of EE increased in 2014-2015 compared to 2010-2011. Unfortunately, our results did not show the true prevalence since esophageal biopsy was not performed in all cases, but our findings may still provide a rough overview. Similar problems have been reported in previous prevalence studies for the same reason. [22] [23] [24] Memon Z et al. 25 analyzed childhood esophagitis over a period of 30 years and observed that the incidence of EE (>25/HPF) had increased in 2011 compared to 1980-1988 and 2000-2002.
Soon IS et al. 5 searched the literature for the incidence and prevalence of EoE in children and reported that both had increased significantly over the previous two decades. Homan M et al. 19 observed a similar increase in Slovenian children. Many studies have suggested that the prevalence of the disease is increasing, but whether the increased prevalence is real or due to increased use of endoscopic procedures and increased awareness of the disease is still the subject of debate. 26 Prospective well-designed studies will elicit the true prevalence of EE in children.
Treatment modalities for EoE include diet and/or CS. 27, 28 Personalized treatment regimens depending on the presence of allergic desensitization and disease behavior have been generally preferred in recent years. Elemental diet, SFED and TED have been prescribed in previous studies, and elemental diet has been shown to be superior at inducing remission compared to SFED and TED, but is less palatable. [28] [29] [30] [31] Similar histological improvement has been reported in TED and SFED in previous pediatric studies, but TED is commonly preferred since this involves the elimination of less food. On the other hand, there are some limitations to the usefulness of the skin prick/ patch test and specific IgE levels in planning TED. These tests are sometimes unable to detect casual food allergens. 31, 32 In one of our cases, which was reported negative for cow's milk by the skin prick test and specific IgE analysis, TED was prescribed initially, but control endoscopy revealed increased IEC and esophageal fibrosis. SFED was then prescribed, and histological improvement was achieved. CS is generally used for induction in severe EoE, in patients who are unable to tolerate diet restriction and in patients who are negative for allergen sensitization. Low-dose CS may be used for maintenance treatment, but side-effects such as adrenal suppression, bone diseases, and candidiasis should also be considered. 33 
